Key Highlights
- ZBiotics closes $12M Series A funding round, led by Spring Tide Capital.
- Funds to be used for retail expansion, R&D, and launching new products.
- Company’s sales have more than doubled annually, with over 5 million units sold.
Source: Business Wire
Notable Quotes
- “Genetic engineering allows us to make totally new products that address real-world consumer needs, and we’re witnessing a growing interest in our technology and brand.” — Zack Abbott, Ph.D., Co-founder and CEO at ZBiotics
- “We are thrilled to support the team as they continue to expand their revolutionary probiotic platform across many more exciting use cases that address everyday consumer pain points.” — Adam Ramada, Co-managing Partner at Spring Tide Capital
SoHC's Take
ZBiotics is making significant strides in the biotech industry by directly addressing modern health challenges with cutting-edge, genetically engineered probiotics. Their recent $12M funding round, led by influential investors, underscores the growing market demand for innovative health solutions. As ZBiotics expands its product line and retail presence, it is set to redefine consumer health products by offering targeted solutions that address specific needs, from gut health to athletic performance. This is a clear indication that consumers are increasingly valuing transparency and scientific rigor in their wellness products, and ZBiotics is well-positioned to lead this new frontier in biotechnology.
